EUVIMEDAtrasti EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients

Anna Fettiplace iD, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi, Arie Regev iD, Melissa Palmer iD, Don Rockey iD, Robert Fontana, Paul H Hayashi, Hans L Tillmann iD, Adrian M Di Bisceglie iD and 1 more

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18271 ↗

At a glance

Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, 2024. Written by Anna Fettiplace and 12 co-authors. Institution: Patient Safety, AstraZeneca, Cambridge, UK. Major MEDLINE topics: Chemical and Drug Induced Liver Injury, Antineoplastic Agents, Clinical Trials as Topic, Neoplasms. Cited 11 times so far (Crossref); 73 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Drug‐induced liver injury (DILI) is a major concern for oncology drugs in clinical practice and under development. Monitoring cancer patients for hepatotoxicity is challenging as these patients may have abnormal liver tests pre‐treatment or on‐study for many reasons including liver injury due to past oncology treatments, hepatic metastases, medical co‐morbidities such as heart failure, and concomitant medications. At present, there are no regulatory guidelines or position papers that systematically address best practices pertaining to DILI detection, assessment and management in oncology patients.

Aims

The goals of this review are (1) to examine and interpret the available evidence and (2) to make recommendations for detection, monitoring, adjudication, and management of suspected hepatocellular DILI during oncology clinical trials.

Methods

This manuscript was developed by the IQ Consortium (International Consortium for Innovation and Quality in pharmaceutical development) DILI Initiative that consists of members from 17 pharmaceutical companies, in collaboration with academic and regulatory DILI experts. The manuscript is based on extensive literature review, expert interpretation of the literature, and several rounds of consensus discussions.

Results

This review highlights recommendations for patient eligibility for clinical trials with or without primary/metastatic liver involvement, as well as changes in liver tests that should trigger increased monitoring and/or discontinuation of study drug. Guidance regarding causality assessment for suspected DILI events, rechallenge and dose‐modification is provided.

Conclusions

This review brings together evidence‐based recommendations and expert opinion to provide the first dedicated consensus for best practices in detection, assessment, and management of DILI in oncology clinical trials.

Subjects

MeSH terms (MEDLINE)

Chemical and Drug Induced Liver InjuryAntineoplastic AgentsClinical Trials as TopicNeoplasmsHumansPractice Guidelines as TopicLiver Function Tests

Substances

Antineoplastic Agents

Authors and institutions

  • Patient Safety, AstraZeneca, Cambridge, UK.
  • Pharmacovigilance and Patient Safety, AbbVie, North Chicago, Illinois, USA.
  • Independent Consultant, Germany.
  • Benefit-Risk Management and Pharmacovigilance, Bayer Pharmaceuticals, USA.
  • Global Safety, Bayer S.A., Brazil.
  • Global Patient Safety, Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID profiles: Anna Fettiplace, Arie Regev, Melissa Palmer, Don Rockey, Hans L Tillmann, Adrian M Di Bisceglie

Cite

APA

Fettiplace, A., Marcinak, J., Merz, M., Zhang, H. T., Kikuchi, L., Regev, A., Palmer, M., Rockey, D., Fontana, R., Hayashi, P. H., Tillmann, H. L., Di Bisceglie, A. M., & Lewis, J. H. (2024). Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18271

Vancouver

Fettiplace A, Marcinak J, Merz M, Zhang HT, Kikuchi L, Regev A, et al. Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18271

BibTeX
@article{Fettiplace2024,
  author = {Fettiplace, Anna and Marcinak, John and Merz, Michael and Zhang, Hui-Talia and Kikuchi, Luciana and Regev, Arie and Palmer, Melissa and Rockey, Don and Fontana, Robert and Hayashi, Paul H and Tillmann, Hans L and Di Bisceglie, Adrian M and Lewis, James H},
  title = {Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18271}
}
Start for free →